ABOUT BICYCLE THERAPEUTICS
Bicycle Therapeutics is pioneering first in class therapeutics to treat cancer and other debilitating diseases based on its proprietary bicyclic peptides (Bicycles®) platform. Bicycles are a breakthrough new therapeutic class that combine antibody-like affinity and selectivity with small molecule-like tissue penetration, tuneable exposure, flexible pharmacokinetics and chemical synthesis. Bicycle Therapeutics is rapidly advancing towards the clinic in 2017 in collaboration with Cancer Research UK (CRUK), with its lead programme using a Bicycle Drug Conjugate® to selectively deliver toxin to tumours. Bicycle is also exploring the potential of bicyclic peptides as targeted, titratable and rapidly penetrant immunomodulators, overcoming the challenges seen for other agents with long exposure, irreversible effects and attendant toxicities. The company is collaborating in oncology, as evidenced by the recently announced CRUK partnership, and in other areas, such as respiratory and cardiovascular and metabolic disease, through a significant new partnership with AstraZeneca, to realise the full therapeutic potential of the Bicycle technology.
Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the Medical Research Council Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company: Sir Greg Winter, a pioneer in monoclonal antibody development, and Professor Christian Heinis, an accomplished researcher in the field of peptide therapeutics. This technology allows phage presentation of linear Bicycle precursor peptides, followed by an on-phage chemical cyclisation to generate enormously diverse (>1015 variants), structurally constrained, Bicycle libraries. These libraries, which can be varied by loop size, symmetry and scaffolding agent, can then be screened against almost any soluble or cell based target using the proprietary Bicycle screening process. Bicycle Therapeutics is headquartered in Cambridge, U.K. and has U.S. operations in Cambridge, Massachusetts.
Bicycle Therapeutics is backed by a top-tier investor syndicate and closed a $32 million Series A funding round in October 2014 as well as a $52 million Series B funding round in June 2017.